Business context and reporting period
LifeVantage Corporation’s Form 10-K reports the fiscal year ended June 30, 2018, with comparative results for fiscal 2017. Although the request labels the period “2017 Q4,” the filing covers FY2018; it also reports fourth-quarter results. The company sells nutritional supplements, skin-care and other wellness products primarily through independent distributors, with a newer e-commerce model in China.
Financial performance and liquidity
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $203.2 million | $199.5 million |
| Gross profit / margin | $168.4 million / 82.9% | $166.0 million / 83.2% |
| Operating income | $10.3 million | $4.4 million |
| Net income | $5.8 million | $1.6 million |
| Diluted EPS | $0.41 | $0.11 |
| Cash from operating activities | $13.3 million | $6.6 million |
Fourth-quarter revenue was $54.0 million versus $50.6 million in FY2017 Q4; net income was $3.0 million versus $0.1 million. At June 30, 2018, cash was $16.7 million, working capital was $15.1 million, total assets were $51.1 million and total liabilities were $29.2 million. Debt principal was $5.5 million ($2.0 million current and $3.5 million long-term). The company reported compliance with its credit-facility covenants and said existing cash and expected operating cash flow should cover requirements for at least 12 months.
Material changes versus the prior comparable period
- Revenue rose 1.9%, supported by international growth, particularly Japan, and increases in Mexico, Canada and Europe. U.S. and Hong Kong revenue remained affected by restrictions adopted after the company’s 2016 international-distribution review.
- Operating income improved as SG&A fell $5.1 million, primarily because FY2017 included higher legal and accounting costs from that review. FY2018 also included increased investment in the Red Carpet distributor-recruitment program.
- Gross margin declined 0.3 percentage points, to 82.9%, reflecting geographic and product mix; management cited price increases and transfer-pricing accrual adjustments as offsets.
- Active customers increased 3.6% to approximately 116,000, while active distributors declined 1.6% to approximately 63,000.
- Protandim represented 65.9% of revenue; TrueScience represented 10.7%. Combined, the two lines contributed 76.6% of revenue, leaving the business substantially concentrated in these products.
Outlook, risks, contingencies and unusual items
- Management expected gross margin of 82%–84% and anticipated revenue growth from market expansion, new products, distributor tools and the Red Carpet program. No numerical revenue or earnings guidance was provided.
- The company launched its China e-commerce model, opened Germany and Taiwan, and introduced Omega+ and product bundles. Management said bundling and the Vitality Stack supported higher average order sizes.
- The 2017 U.S. tax law led to a $1.4 million deferred-tax revaluation charge; FY2018’s effective tax rate was 39.7%. The company reported no deemed-repatriation tax payable after applying foreign tax credits.
- A purported class action filed in January 2018 alleges the company operated a pyramid scheme. The case was transferred to Utah in July 2018. The company recorded no accrual, stating that a loss was not probable or estimable; an adverse outcome could be material. Earlier securities and derivative suits were dismissed.
- An FDA warning letter issued in April 2017 concerning website claims was reported as resolved. Management and the auditor concluded internal controls over financial reporting were effective at June 30, 2018; a material weakness related to international distribution had been identified in 2016 and remediation steps were taken.
- Key risks include distributor retention and compliance, direct-selling and product-claim regulation, product concentration, international and currency exposure, third-party manufacturing and logistics, inventory management, litigation, and restrictive secured-debt covenants.
- Notable related-party payments included $4.0 million to Real Salt Lake under a marketing partnership with a major shareholder, and $3.0 million to Gig Economy Group for software development; a former director was a majority owner and officer of Gig Economy Group.
Important facts for investors to verify
- Whether FY2018 revenue growth and improved profitability continued after the reported period, and whether fourth-quarter momentum persisted.
- Distributor and customer trends, especially the decline in active distributors and the performance of the U.S. market.
- Progress and economics of China e-commerce and the newer market launches, including whether they deliver sustainable growth.
- The status, potential exposure and any subsequent developments in the pyramid-scheme class action, as well as distributor and product-claim compliance.
- Debt repayment, covenant headroom and the effect of the amended 5.68% loan rate and $8.0 million minimum working-capital covenant.
- Product concentration, inventory obsolescence charges ($1.4 million in FY2018), foreign-exchange sensitivity, and the business rationale and oversight for related-party arrangements.